Guangdong Drug Mishap new regulations.docVIP

 PAGE \* MERGEFORMAT 10 Guangdong Drug Mishap new regulations Recently, Guangdong Province issued ‘on the drug trade, Guangdong Province, to seek the relevant rules (draft) revised opinion’ (hereinafter ‘the Rules’), a directory-based medicine since the introduction of the new year, China’s first province in the rules published tenders . However, the first role does not bring much glory to the Guangdong Province, but because one of the bidding rules for the industry suffered criticism. Special guest (in no particular order the following) Our special observers Genghong Wu Sinopharm Group Co. Ltd. senior industry researcher dry Greenfield Our special observers Long Kang Pharmaceutical Co., Ltd., general manager of Guangdong Dong Jing Our special observers Pharmaceutical Co., Ltd. of Shenzhen City Star Silver Deputy Ze West Anhan Feng SUN Hui Pharmaceutical Co., Ltd. Marketing Director ◆ Current Chair: Wang Shaoting [Collision of ideas] Imbalance between quality and price tender Medical observers: drug transaction in the base, the ‘rule’ proposed a ‘double envelope’ system of accreditation, and economic and technological standard 10 points, 90 points marked the proportion of business computing composite score. In this regard, how do you evaluate the? Dong Jing: We all know that in recent years for the completion of the new GMP certified pharmaceutical companies in the technological aspects of put a lot of manpower, money and time, which leads to overall production costs of drugs rose an average of about 20%. However, the ‘rule’ is not only subject to economic and technical scores to 10 percent, the economy is still based medicine given to complete the new technical standards of pharmaceutical GMP certification scores 3 points. This is clearly the seven ministries jointly issued the ‘medical institutions centralized drug procurement practices’ and ‘quality first, price reasonable,’ contrary to the principle. In fact, in recent years to